Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 82.5% in May

Fresenius SE & Co. (OTCMKTS:FSNUYGet Free Report) was the target of a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 8,663 shares, a drop of 82.5% from the May 14th total of 49,381 shares. Based on an average trading volume of 403,780 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Fresenius SE & Co. Trading Down 0.1%

Shares of FSNUY traded down $0.01 during trading hours on Friday, hitting $10.92. The company had a trading volume of 108,832 shares, compared to its average volume of 118,385. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average price is $11.86 and its 200 day moving average price is $13.34. The firm has a market cap of $24.60 billion, a P/E ratio of 14.56 and a beta of 0.64.

Fresenius SE & Co. (OTCMKTS:FSNUYGet Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. The company had revenue of $6.75 billion for the quarter, compared to analysts’ expectations of $6.79 billion. On average, research analysts predict that Fresenius SE & Co. will post 1.05 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy”.

Get Our Latest Analysis on FSNUY

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

Read More

Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.